Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HSD17B13 | Q7Z5P4 | 4/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910238 | 0.83 | GPR84 (0.47) | DRD2DRD3GPR84ACACB | |
| SCHEMBL1996584 | 0.81 | L3MBTL1 (0.36) | DRD2DRD3MAPK14KDRADORA2B | |
| SCHEMBL1033958 | 0.81 | TYR (0.46) | DRD2DRD3HSD17B13TNFGPR84 | |
| SCHEMBL1130169 | 0.79 | DRD2 (0.42) | DRD2DRD3MAPK14KDRADORA2B | |
| SCHEMBL8229121 | 0.77 | TYR (0.43) | DRD2DRD3HSD17B13MCHR1GPR84 | |
| SCHEMBL1998193 | 0.76 | KDR (0.52) | DRD2DRD3MAPK14KDRHTR1A | |
| SCHEMBL2001744 | 0.76 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL7640918 | 0.73 | KAT2B (0.48) | DRD2DRD3MAPK14TNF | |
| SCHEMBL5005631 | 0.72 | ACACB (0.44) | DRD2DRD3KDRHSD17B13MCHR1 | |
| SCHEMBL1038378 | 0.72 | GRM2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763522-B1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8334289-B2 | Pyridin-2-one compounds and their use as modulators of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110245266-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-7960386-B2 | 1-(4-{4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-4-methylpyridin-2(1H)-one; treatment of schizophrenia and/or depression | ABBOTT GMBH & CO. KG (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20080261992-A1 | Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1763522-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005118571-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245266-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | DRD3, DRD2, PTGDR | DRD2 2/4885DRD3 1/4885MAPK14 2395/4885 |
| US-20080261992-A1 | Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor | DRD3, DRD2, MTNR1A | DRD2 2/4885DRD3 1/4885MAPK14 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.